Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 9 trials

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Early P 1 (1)
P 1 (2)
P 2 (1)
P 3 (1)

Trial Status

Recruiting4
Not Yet Recruiting2
Unknown1
Enrolling By Invitation1
Active Not Recruiting1

Clinical Trials (9)

Showing 9 of 9 trials
NCT07375563Phase 3RecruitingPrimary

Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

NCT07318831Phase 2Not Yet RecruitingPrimary

Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children

NCT07223606Unknown

Fecal Microbiota Transplant for Neuroblastoma in a Single Patient

NCT07064746RecruitingPrimary

Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

NCT03189706Early Phase 1Active Not RecruitingPrimary

Study of Chemoimmunotherapy for High-Risk Neuroblastoma

NCT06703944Enrolling By InvitationPrimary

Risk Model for Metastasis Detection of Neuroblastoma

NCT06674265Phase 1Recruiting

Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma

NCT06873672Not Yet Recruiting

Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China

NCT06836505Phase 1RecruitingPrimary

Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.

Showing all 9 trials

Research Network

Activity Timeline